Fin Cascade
Get Android appGet iOS app

Prices as of 9 Oct 2026 close · Not investment advice

Kwality Pharmaceuticals Limited

NSE: KPLPharmaceuticals

Share price

₹3,564.30

+0.88% close of 9 Oct 2026

Market cap ₹3,564 CrP/E 43.5

Price-based ratios (P/B, dividend yield, EV/EBITDA) are as of 8 Oct 2026, the close above is 9 Oct 2026.

Business score

How strong the business is, in one number. The parts behind it are in Pro.

69

out of 100 · worked out 9 Oct 2026

How the business score works

Your ratios

The numbers you want to see first. Tap Edit to change them.

Market cap

₹3,564 Cr

P/E ratio

43.5

P/B ratio

11.1

ROCE

24.1%

ROE

22.5%

Dividend yield

0.0%

Price & valuation chart

How the share price and its valuation have moved. Hover over the chart to see any day. Prices as of the last close.

Prices as of 9 Oct 2026 close52-week high ₹3,844.9052-week low ₹838.20

Answers

Simple answers to the questions investors ask most, from the company's own numbers.

How fast it has been growing

Sales grew 37.9% over the past year, and 7.4% a year over its longer record. Meanwhile what it keeps of every 100 rupees of sales slipped from 31.0% to 24.3% over the last four years.

Whether it grew faster than its sector

It grew 7.4% a year against a sector median of 13.1% — 5.7 percentage points slower.

Room to re-rate, or risk of de-rating

At 43.5× earnings it costs 1.8× the market, which pays 24.1× across 2199 companies we can price. Its own industry sits at 79.4×, across 5 companies. It is against its own five-year median of 20.6×, the 92nd percentile of its own range.

Whether growth justifies the valuation

Priced at 1.5 times its growth rate, on earnings growth of 29%.

Profit growthPrice per ₹1 profitPer 1% growth
Kwality Pharmaceuticals Limited — this one29%/yr43.5×₹1.5
Divi's Laboratories13%/yr83.1×₹6.4
Torrent Pharmaceuticals22%/yr79.4×₹3.6
Zydus Lifesciences32%/yr23.2×₹0.72
Laurus Labs Limited4%/yr100.5×₹25.1
Cipla10%/yr29.4×₹2.9

Compared with companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

How it compares with its peers

Against companies the exchange files under the same label (Pharmaceuticals), it ranks 27 of 130 on returns, 88 of 127 on growth, 41 of 130 on margin. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

What makes it hard to beat — and is that still true?

A wide advantage: it earns 24.1% on capital, ahead of 79% of companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

Whether its growth pays for itself

Yes — Over the last five years it made ₹215 crore of cash from the business, spent ₹198 crore on plant and equipment, and returned ₹17 crore to lenders and shareholders. And the profit is real: of every 100 rupees it reported over 12 years, about 85 arrived as cash. Its cash comes back more slowly than it used to: it went from being waiting 60 days for its cash to waiting 128 days for its cash.

Profit reality check

Is the profit real cash? Simple checks on the accounts. Facts only, not advice.

7 of 9 checks clear · 78%

How the profit check works

Latest result · Q1 FY27

What the last results showed. Whether management kept its word is in Pro.

Profit rose 113.52% to Rs 25.62 crore.

Announced 10 Aug 2026 · Consolidated · Unaudited

Revenue

₹162 Cr

Revenue vs last year

+45.6%

Revenue vs last quarter

+3.3%

Net profit

₹26 Cr

Profit vs last year

+113.5%

Profit vs last quarter

+2.5%

Net margin

15.8%

Checklist before you investPRO

Points for and against, in one list.

Key numbers & peers

The main numbers grouped by topic, and how the company compares with similar ones.

Price

Market cap
₹3,564 Cr
Prev close
₹3,564.30
52w High
₹3,949
52w Low
₹829
Enterprise value
₹3,690 Cr
Beta
0.7
Price CAGR 1y
306.0%
Price CAGR 3y
122.0%
Price CAGR 5y
32.0%
Price CAGR 10y
65.0%

Ratios

Return on assets
11.3%
PEG ratio
1.6
P/E ratio
43.5
P/B ratio
11.1
EV / EBITDA
27.3
Industry P/E
37.6
ROCE
24.1%
ROCE 5y average
35.0%
ROE
22.5%
Debt / Equity
0.4
Interest coverage
9.1
Dividend yield
0.0%
ROE 3y average
18.0%
ROE last year
23.0%

Annual P&L

Annual revenue
₹503 Cr
Annual profit
₹67 Cr
Operating margin
24.0%
Net profit margin
13.3%
EBITDA margin
23.5%
Sales growth 3y
26.1%
Sales growth 5y
13.9%
Profit growth 3y
29.0%
Profit growth 5y
35.0%
EPS
₹64.9
Sales growth TTM
38.0%
Profit growth TTM
88.0%
Dividend payout
0.0%

Quarter P&L

Sales latest quarter
₹162 Cr
Profit latest quarter
₹26 Cr
YoY quarterly sales growth
45.6%
YoY quarterly profit growth
116.7%
OPM latest quarter
25.3%

Balance Sheet

Book Value
₹331
Face Value
₹10.0
Total debt
₹130 Cr
Total cash
₹4 Cr
Borrowings
₹130 Cr
Reserves / Equity
32.1

Cash Flow

Operating cash flow
₹17 Cr
Free cash flow
-₹29 Cr
FCF yield
-1.1%
Net cash flow
-₹11 Cr

Shareholding

Promoter holding
54.9%
FII holding
3.1%
DII holding
0.6%
Public holding
41.5%

Peer comparison

CompanyPrice ₹P/EMkt cap ₹ CrDiv yield %Profit qtr ₹ CrProfit var %Sales qtr ₹ CrSales var %ROCE %
Sun Pharma.Inds.1,786.5533.94,28,6530.902,901.26.015,299.910.520.5
Divi's Lab.9,544.9085.02,53,3870.31902.065.53,080.027.822.0
Torrent Pharma.4,712.2580.31,79,2390.81566.05.84,921.054.915.2
Zydus Lifesci.1,144.7023.41,14,1840.09990.2-35.18,017.022.021.1
Laurus Labs2,034.30100.51,09,9160.10362.1125.52,026.329.117.8
Cipla1,325.9529.91,07,1200.98785.6-39.27,119.32.315.5
Mankind Pharma2,478.9048.01,02,3900.04574.129.64,030.612.913.5
Kwality Pharma3,640.7046.33,7780.0025.6114.8162.445.624.1
Median415.5534.72,1640.0713.229.6162.418.615.0

Competes with: Aurobindo Pharma, Cipla, Divi's Laboratories, Dr Reddy's Laboratories, Laurus Labs Limited, Lupin, Mankind Pharma Limited, Sun Pharmaceutical, Torrent Pharmaceuticals, Zydus Lifesciences

Quarterly results

Sales and profit for each of the last 13 quarters. Newest on the right. ₹ crore.

Consolidated · to 30 Jun 2026
Line itemJun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales67707892809084116111111123157162
Expenses5454617163706790878693118121
Material Cost85
Change in Inventories1.62
Purchases of Stock-in-Trade0.47
Employee Cost15
Other Expenses19
Operating Profit14151721172018262425303941
OPM %20222122222221222223242525
Other Income001-7001101-011
Exceptional items (within Other Income)0
Interest2233232233233
Depreciation5555455555555
Profit before tax78106111311191718223234
Tax %25242129253325243023282025
Net Profit5684889141214162526
EPS in Rs5.226.017.414.208.068.168.22141214152425

Profit & loss

Yearly sales, costs and profit for 12 years, plus the last 12 months (TTM). ₹ crore.

Consolidated · to 31 Mar 2026
Line itemMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales527498137166139262456251307370503554
Expenses496989126150125233285190241290385419
Operating Profit35912161429172616680118135
OPM %679891011382422222424
Other Income00111424-14-5222
Interest112223337109.881111
Depreciation1233346111520182020
Profit before tax126711112116226315489106
Tax %414842393125302625242625
Net Profit113488151201924406781
EPS in Rs0.921.553.234.397.288.02151161923386578
Dividend Payout %009000000000

Compounded growth

Average yearly growth over different spans, as stored. A span can cross a demerger or an acquisition.

Compounded sales growth

10 years
21%
5 years
14%
3 years
26%
TTM
38%

Compounded profit growth

10 years
44%
5 years
35%
3 years
29%
TTM
88%

Stock price CAGR

10 years
65%
5 years
32%
3 years
122%
1 year
306%

Return on equity

10 years
26%
5 years
27%
3 years
18%
Last year
23%

Balance sheet

What the company owns and what it owes, at the end of each year. ₹ crore.

Consolidated
Line itemMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital455101010101010101010
Reserves15172019273651171190214254321
Borrowings8131926293541549098112130
Other Liabilities10172640395264105707271130
Total Liabilities37517196105133166341361394447592
Fixed Assets1313172029435792120139146156
CWIP000000312140017
Investments124554500000
Other Assets243750707186102237226255302420
Total Assets37517196105133166341361394447592

Cash flows

Real money coming in and going out each year — from the business, from investments and from loans. ₹ crore.

Consolidated
Line itemMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity1-34-1146276141435317
Cash from Investing Activity-1-2-7-6-12-18-23-63-48-26-29-35
Cash from Financing Activity1655-212161-17-147
Net Cash Flow102-1-0043-6-110-11
Free Cash Flow-0-5-2-72-1235-41728-29

Ratios

How fast customers pay, how long stock sits, and how well capital earns — year by year.

Consolidated
Line itemMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days6389849884795055104136152203
Inventory Days6167715434943897310187167111
Days Payable4063658052965863117106112144
Cash Conversion Cycle8593907367773090297217208170
Working Capital Days354120182043246011810198128
ROCE %91319192218269819161824

Shareholding pattern

Who owns the company — founders (promoters), foreign funds, Indian funds and the public. In %.

Consolidated · to 30 Jun 2026
Line itemSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters555555555555555555555555
FIIs0000000000.502.793.13
DIIs0.010.01000.020.030.320.330.330.330.360.56
Public454545454545454545444241
No. of Shareholders6,2915,7865,6955,2737,4878,9479,42010,11511,59510,70910,55513,279

Price trend

The price as a Renko brick chart: small moves drop out so the bigger path stands out.

Change over 1 year +308.9% (₹871.65 → ₹3,564.30)Brick size ₹178.29 (fixed)Bricks 16
₹1,000₹2,000₹3,000₹3,564Feb '26Jun '26
Price moved up one brickPrice moved down one brickLast close ₹3,564.30 on 9 Oct 2026

Every brick is the same size, about one typical day's move. A new brick needs a full brick's move; turning the other way needs two. Bricks show where the price went, not where it will go.

Open interestPRO

Where option traders are positioned on this stock.

Industry numbers

The numbers that matter most in this industry, from the company's own filings.

the company's own unlisted debt securities in default at period end

0.00cr

2026-06-30

the company's own loans / revolving facilities in default at period end (standalone filing)

0.00cr

2026-06-30

net debt from the filed balance sheet at the newest year end: Borrowings − Cash Equivalents − Investments (Current); negative = net cash

126inr_cr

2026-03-31

guarantees / comfort given for promoter, promoter group, directors and KMP

0.00cr

2026-03-31

loans outstanding to promoter, promoter group, directors and KMP (governance filing)

0.00cr

2026-03-31

security given for the borrowing of promoter, promoter group, directors and KMP

0.00cr

2026-03-31

News

News and filings about Kwality Pharmaceuticals Limited. Open one to see why it matters.

No recent news for this company.

Supply chain

Who it buys from, sells to and competes with — as recorded in our map of company links.

Competes with

Uses as raw material

  • carbocisteine
  • cisplatin
  • decitabine
  • gemfibrozil
  • lysine acetylsalicylate
  • packing material for pharma products
  • raw materials including APIs

About

What the company is, from our own records: where it sits, where it makes things, and what it is made of.

Sector
Healthcare
Industry
Pharmaceuticals
Classification
Healthcare › Pharmaceuticals
ISIN
INE552U01010

Plants

  • Kwality Pharma Unit-1 Block A & Block W1
  • Kwality Pharma Unit-2
  • Kwality Pharma Unit-3
  • Kwality Pharma Unit-4
  • Kwality Pharma Unit-6

News impact

Big market events that reach Kwality Pharmaceuticals Limited, and how the effect spreads.

No recent market events reach this company.

Dividends, splits & big trades

Money paid out, share splits and buybacks, and big buys or sells by funds and insiders.

No dividends, splits or big trades on record.

Documents

Annual reports, results presentations and earnings calls, straight from the source.

Facts from company filings and exchange data. Not investment advice: nothing here tells you to buy or sell.